PCRX Pacira Pharmaceuticals Inc.

45.26
-0.54  -1%
Previous Close 45.8
Open 45.5
Price To Book 6.17
Market Cap 1860829461
Shares 41,114,217
Volume 365,391
Short Ratio
Av. Daily Volume 500,390

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181152889
  2. 8-K - Current report 181152079
  3. SC 13D - General statement of acquisition of beneficial ownership 181132757
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988083
  5. 8-K - Current report 18986729

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
Approval announced April 6, 2018.
EXPAREL
Post surgical pain

Latest News

  1. New Retrospective Analysis Demonstrates Significant Reductions in Postsurgical Pain and Opioid Requirements with EXPAREL in Cesarean Section Patients
  2. Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com
  3. Pacira Pharmaceuticals Inc (PCRX): Are Hedge Funds Right About This Stock?
  4. Pacira Pharmaceuticals to Present at the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference
  5. Lilly (LLY) Hits Fresh High: Is There Still Room to Run?
  6. New Data Show EXPAREL Plays a Key Role in Achieving Significant Reductions in Opioid Use, Hospital Stay and Total Hospitalization Costs Following Painful Knee Replacement Surgery
  7. See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
  8. Is Pacira Pharmaceuticals Inc’s (NASDAQ:PCRX) CEO Paid Enough Relative To Peers?
  9. Pacira Pharmaceuticals CMO Presents at FDA Advisory Committee Meeting Focused on Assessment of Opioid-Sparing Outcomes in Clinical Trials
  10. Edited Transcript of PCRX earnings conference call or presentation 1-Nov-18 12:30pm GMT
  11. Report: Developing Opportunities within Rayonier Advanced Materials, Health Insurance Innovations, Columbus McKinnon, A. O. Smith, Pacira Pharmaceuticals, and Altice — Future Expectations, Projections Moving into 2018
  12. Pacira Pharmaceuticals to Present at Healthcare Conferences in November
  13. Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates
  14. Centers for Medicare and Medicaid Services and American Dental Association Establish New Reimbursement for EXPAREL
  15. Pacira: 3Q Earnings Snapshot
  16. Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results
  17. Aetna Offers Expanded Coverage for EXPAREL® in Select Ambulatory Surgical Centers 

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181152889
  2. 8-K - Current report 181152079
  3. SC 13D - General statement of acquisition of beneficial ownership 181132757
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988083
  5. 8-K - Current report 18986729
  6. 8-K - Current report 18945812
  7. 8-K - Current report 18902393
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18803438
  9. 8-K - Current report 18801849
  10. DEF 14A - Other definitive proxy statements 18784267